ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet oder das Unternehmen), der weltweit führende Anbieter von schlauchloser Insulinpumpentechnologie mit seiner Marke Omnipod, ...

BILLERICA, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System (Omnipod ...

Insulet, which specializes in tubeless insulin pump technology with its Omnipod brand of products, today announced it has received FDA 510(k) clearance for the Omnipod 5 App for iPhone. This makes ...

Insulet Corporation PODD recently made its Omnipod 5 Automated Insulin Delivery (“AID”) system commercially available in Canada for people with type 1 diabetes (ages two years and above). Omnipod 5 is ...

The expanded approval for the Omnipod 5 system now allows automated insulin delivery (AID) for adults with type 2 diabetes, offering a new option for better glucose management without daily injections ...

Insulet stock was surging Tuesday after the healthcare company said its Omnipod 5 Insulin System got approval from the Food and Drug Administration.

Insulet Corp. PODD recently announced the commercial launch of its Omnipod 5 Automated Insulin Delivery (“AID”) System for individuals aged two years and older with type 1 diabetes (T1D) in the United ...

(HealthDay News) — On Monday, the US Food and Drug Administration approved the Insulet Omnipod 5 insulin delivery system for patients with type 2 diabetes. It is the first such system for use by ...

Aug 7 (Reuters) - Medical device maker Insulet (PODD.O), opens new tab beat Wall Street estimates for second-quarter profit and revenue on strong demand for its wearable insulin pumps, sending its ...